In a groundbreaking study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases—two rare, often fatal lysosomal storage disorders that cause ...

Hamilton, ON, Nov. 14, 2024, In a groundbreaking study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases—two rare, often fatal lysosomal ...

Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept ...

Axovant Gene Therapies, a clinical-stage company, announced that the US Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigational New Drug (IND) Application to ...

Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...

Tay-Sachs and Sandhoff diseases, genetic disorders affecting the brain, have no effective treatment and are typically fatal within the first years of life. Scientists have reasoned that replacing the ...

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage ...

Genetic neurodegenerative disorders like Tay-Sachs and Sandhoff disease currently have no effective treatments. A possible strategy is replacing affected cells with healthy ones in order to slow the ...

Cherry-red spots are seen in metabolic diseases and in central retinal artery occlusion. The appearance is that of a red spot surrounded by a halo of milky white material. Cherry-red spots occur in ...